Clinical Trials
15 trialsNCT06535607 2026-05-26
eVOLVE-02
AstraZeneca
Phase 2 Recruiting
NCT07216703 2026-05-22
TroFuse-036
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04389632 2026-05-11
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT03556839 2026-04-21
BEATcc
Grupo Español de Investigación en Cáncer de Ovario
Phase 3 Completed
NCT03786081 2026-04-14
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Seagen Inc.
Phase 1/2 Terminated
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT04644068 2026-02-19
PETRA
AstraZeneca
Phase 1/2 Active not recruiting
NCT03635567 2026-02-04
KEYNOTE-826
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06400472 2026-01-14
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Recruiting
NCT00980954 2025-12-31
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04982237 2025-11-19
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Akeso
Phase 3 Active not recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04016389 2025-08-12
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
University Health Network, Toronto
Phase NA Recruiting
NCT06977594 2025-06-24
Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
Seoul National University Hospital
Phase NA Not yet recruiting
NCT06859775 2025-06-06
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting